Second, the favorable effect of ILK-MSCs seen in our study could not be directly translated to clinical practice, because animals in our study did not receive optimized pharmacological therapies well established to inhibit myocardial remodeling and improve cardiac function post-MI, thus whether an add-on effect could be obtained on the basis of drug therapy is uncertain and needs confirmation in further studies. The gene discussed is ILK; the disease is myocardial infarction.